Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07674160

Effect of Simethicone on Colon Preparation During Water Exchange Colonoscopy

Background: Colonoscopy reduces colorectal cancer mortality by enabling early detection and removal of adenomas. Its effectiveness, however, depends heavily on bowel preparation quality and mucosal visibility. Simethicone, an anti-foaming agent, decreases intraluminal bubbles and improves visualization; studies in conventional air-insufflation colonoscopy generally show benefits for cleanliness and patient comfort, but evidence in water-exchange (WE) colonoscopy remains limited.Objective: To evaluate whether adding oral simethicone to a split-dose polyethylene glycol (PEG) regimen further improves bowel cleanliness and procedural performance in WE colonoscopy.Methods: Adults undergoing outpatient colonoscopy will be randomly assigned (1:1) to a simethicone group or a control group, with a planned enrollment of 180 participants. All procedures will use the WE insertion technique, and endoscopists will be blinded to group allocation. The primary endpoint is the Boston Bowel Preparation Scale (BBPS); adequate preparation is defined as a total score ≥6 with all segment scores ≥2. Secondary endpoints include bubble score and CEBuS, adenoma detection rate (ADR), polyp detection rate (PDR), cecal intubation rate and time, withdrawal time, volume of water used and flushing/irrigation metrics, and patient-reported tolerability and satisfaction.Expected Results: Compared with PEG alone, adding simethicone is expected to (1) increase the proportion of adequate BBPS preparations, (2) reduce bubble coverage, (3) maintain or potentially improve ADR/PDR, and (4) enhance patient tolerability and satisfaction.Conclusion: If effective, this intervention would provide a simple, low-cost strategy to optimize the quality of WE colonoscopy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Consecutive patients undergoing screening, surveillance, or diagnostic colonoscopy.
  • Procedures performed by participating endoscopists.
  • Ability to provide written informed consent.

Exclusion criteria

  • Colonoscopy performed using air insufflation or water immersion technique.
  • History of colorectal surgery (e.g., colectomy or colostomy).
  • Known or suspected colonic obstruction or severe stricture.
  • Requirement for inpatient bowel preparation.
  • Known allergy or hypersensitivity to simethicone.
  • Unable or unwilling to provide informed consent.

Treatment and study plan

Simethicone with PEG

Drug

All participants followed a standardized bowel preparation protocol consisting of 10 mg of bisacodyl and 2 liters of PEG solution administered in a split-dose regimen. Participants in the simethicone group additionally received 30 mL of simethicone (600 mg), with 15 mL added to each 1-liter dose of PEG solution.

PEG

Drug

All participants followed a standardized bowel preparation protocol consisting of 10 mg of bisacodyl and 2 liters of PEG solution administered in a split-dose regimen.

Primary outcomes

  1. Boston bowel preparation scale (BBPS)

    Time frame: At the time of colonoscopy.

    Bowel preparation quality assessed using the Boston Bowel Preparation Scale (BBPS). Adequate preparation is defined as a total score ≥6 with all segment scores ≥2.

Secondary outcomes

  1. Bubble score assessed using a 4-point bubble scale

    Time frame: During the colonoscopy procedure.

    Bubble score assessed during colonoscopy using a 4-point scale (0-3) for each colon segment, where higher scores indicate more bubbles.

  2. Colon Endoscopic Bubble Scale(CEBuS)

    Time frame: During the colonoscopy procedure.

    Bowel cleanliness assessed using the Colon Endoscopic Bubble Scale (CEBuS), categorized based on the percentage of mucosal surface obscured by bubbles (e.g., <5%, 5-50%, >50%).Higher scores indicate poorer visibility due to bubbles.

  3. Adenoma detection rate (ADR)

    Time frame: one week

  4. Polyp detection rate (PDR)

    Time frame: one week

  5. Cecal intubation rate

    Time frame: At the time of colonoscopy.

    Proportion of procedures in which the cecum is successfully reached.

  6. Cecal intubation time

    Time frame: During the colonoscopy procedure.

    Time from insertion to successful cecal intubation, measured in minutes.

  7. Withdrawal time

    Time frame: During the colonoscopy procedure.

    Time from cecal intubation to scope withdrawal, measured in minutes.

  8. Volume of water infused

    Time frame: During the procedure.

    Total volume of water infused during colonoscopy, measured in milliliters.

  9. Volume of fluid aspirated

    Time frame: During the procedure

    Total volume of fluid aspirated during colonoscopy, measured in milliliters.

  10. Patient-reported pain score

    Time frame: Immediately after the procedure.

    Pain assessed using a visual analog scale (VAS) ranging from 0 (no pain) to 10 (worst pain imaginable).

  11. Patient satisfaction score

    Time frame: Immediately after the procedure.

    Patient satisfaction assessed using a numeric rating scale from 0 to 10, where higher scores indicate greater satisfaction.

Study contacts

Contact information is provided by the study sponsor or research team.

Chih -Wei Tseng

CONTACT

[email protected]

+886-5-2648000

Sponsors and collaborators

Lead sponsor

Dalin Tzu Chi General Hospital

Other

Registry information

Official study title

Effects of Simethicone on Colon Preparation in Water Exchange Colonoscopies: a Randomized Controlled Study

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jun 29, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.